Kane Biotech Inc. (TSXV:KNE)
Canada
· Delayed Price · Currency is CAD 0.0350
0.00 (0.00%)
At close: Mar 9, 2026
Kane Biotech Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.57 | 2.08 | 0.15 | 0.16 | 1.61 | 1.34 | Upgrade
|
| Revenue Growth (YoY) | -71.44% | 1296.75% | -4.95% | -90.25% | 19.84% | -20.78% | Upgrade
|
| Cost of Revenue | 0.67 | 1.21 | 0.04 | 0.04 | 1.04 | 0.81 | Upgrade
|
| Gross Profit | -0.1 | 0.87 | 0.11 | 0.11 | 0.57 | 0.53 | Upgrade
|
| Selling, General & Admin | 1.79 | 3.08 | 2.41 | 2.53 | 4.07 | 3.43 | Upgrade
|
| Research & Development | 0.91 | 1.51 | 1.05 | 1.04 | 1.31 | 1.29 | Upgrade
|
| Operating Expenses | 2.7 | 4.59 | 3.46 | 3.57 | 5.39 | 4.71 | Upgrade
|
| Operating Income | -2.8 | -3.72 | -3.35 | -3.46 | -4.82 | -4.18 | Upgrade
|
| Interest Expense | -0.29 | -0.55 | -1.22 | -0.82 | -0.42 | -0.12 | Upgrade
|
| Interest & Investment Income | 0.02 | 0 | 0.01 | 0.02 | 0.12 | 0.04 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.01 | -0.01 | 0 | -0.02 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -3.07 | -4.27 | -4.56 | -4.28 | -5.11 | -4.27 | Upgrade
|
| Asset Writedown | -0.21 | -0.21 | -0.01 | - | -0.07 | -0.04 | Upgrade
|
| Other Unusual Items | 0.02 | - | 0 | 0.25 | 0.32 | 0.46 | Upgrade
|
| Pretax Income | -3.26 | -4.47 | -4.56 | -4.02 | -4.85 | -3.85 | Upgrade
|
| Income Tax Expense | -1.31 | -1.31 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -1.95 | -3.16 | -4.56 | -4.02 | -4.85 | -3.85 | Upgrade
|
| Earnings From Discontinued Operations | -1.31 | 9.26 | -0.47 | 0.13 | - | - | Upgrade
|
| Net Income to Company | -3.26 | 6.1 | -5.03 | -3.89 | -4.85 | -3.85 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.25 | 0.13 | Upgrade
|
| Net Income | -3.26 | 6.1 | -5.03 | -3.89 | -4.6 | -3.72 | Upgrade
|
| Net Income to Common | -3.26 | 6.1 | -5.03 | -3.89 | -4.6 | -3.72 | Upgrade
|
| Shares Outstanding (Basic) | 189 | 134 | 127 | 121 | 113 | 109 | Upgrade
|
| Shares Outstanding (Diluted) | 189 | 155 | 127 | 121 | 113 | 109 | Upgrade
|
| Shares Change (YoY) | 34.53% | 22.23% | 5.32% | 7.20% | 3.67% | 31.97% | Upgrade
|
| EPS (Basic) | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 | -0.03 | Upgrade
|
| EPS (Diluted) | -0.02 | 0.05 | -0.04 | -0.03 | -0.04 | -0.03 | Upgrade
|
| Free Cash Flow | -3 | -4.14 | -2.09 | -3.05 | -2.48 | -3.97 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.03 | -0.02 | -0.03 | -0.02 | -0.04 | Upgrade
|
| Gross Margin | -16.60% | 41.91% | 73.48% | 71.48% | 35.36% | 39.27% | Upgrade
|
| Operating Margin | -486.26% | -178.66% | -2248.93% | -2206.05% | -299.63% | -311.93% | Upgrade
|
| Profit Margin | -566.62% | 293.05% | -3379.05% | -2481.86% | -286.39% | -277.04% | Upgrade
|
| Free Cash Flow Margin | -522.57% | -198.77% | -1403.79% | -1947.70% | -153.99% | -295.64% | Upgrade
|
| EBITDA | -2.72 | -3.62 | -3.23 | -3.3 | -4.73 | -4.12 | Upgrade
|
| EBITDA Margin | - | -174.05% | - | - | -294.36% | - | Upgrade
|
| D&A For EBITDA | 0.07 | 0.1 | 0.12 | 0.16 | 0.08 | 0.07 | Upgrade
|
| EBIT | -2.8 | -3.72 | -3.35 | -3.46 | -4.82 | -4.18 | Upgrade
|
| EBIT Margin | - | -178.66% | - | - | -299.63% | - | Upgrade
|
| Revenue as Reported | 2.08 | 2.08 | 0.15 | 0.16 | 1.61 | 1.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.